Which of the following represents an appropriate management of Pehe’s disease in a young patient?
**Core Concept**
Pehe's disease, also known as psoriatic arthritis (PsA), is a chronic inflammatory arthritis associated with psoriasis. It involves both systemic inflammation and localized joint damage, making early and effective management crucial to prevent long-term consequences.
**Why the Correct Answer is Right**
The management of PsA in a young patient involves a multidisciplinary approach, including pharmacological, physical, and lifestyle modifications. The correct answer involves the use of biologic agents, specifically tumor necrosis factor-alpha (TNF-alpha) inhibitors, which have been shown to be effective in reducing inflammation and slowing disease progression in PsA patients. This class of medications targets the TNF-alpha pathway, which plays a key role in the inflammatory cascade.
**Why Each Wrong Option is Incorrect**
**Option A:** Nonsteroidal anti-inflammatory drugs (NSAIDs) may provide symptomatic relief but do not address the underlying inflammatory process and are not sufficient as monotherapy for PsA management.
**Option B:** Steroids can be used as a short-term option for managing inflammation but are not recommended for long-term use due to their side effects and the risk of disease flare upon withdrawal.
**Option C:** Methotrexate, a disease-modifying antirheumatic drug (DMARD), is often used in PsA management but may not be sufficient as monotherapy in young patients, where biologic agents are often preferred.
**Clinical Pearl / High-Yield Fact**
In PsA management, it's essential to consider the presence of psoriasis and its severity when selecting a treatment approach, as some medications may exacerbate skin symptoms.
**Correct Answer: C. Methotrexate and a TNF-alpha inhibitor.**